N2OFF shares rise 12.96% intraday after announcing MITOLINE algorithm advancements targeting $120B inflammatory metabolic diseases market.

N2OFF, Inc. surged 12.96% intraday following recent positive developments in its biotech and renewable energy initiatives. The stock's rally coincided with announcements of advancements in MitoCareX Bio’s mitochondrial drug discovery platform, including positive in vitro results for its small-molecule candidates targeting resistant cancers. Additionally, N2OFF reported progress in European solar and energy storage projects, including expanded battery storage capacity in Germany and Italy. These updates, combined with shareholder approval of the MitoCareX acquisition in late September 2025 and regaining Nasdaq compliance, reinforced investor confidence in the company’s dual-sector strategy. While an early warning disclosure regarding diluted ownership in Plantify Foods was reported, it was not linked to the intraday price action. The surge reflects optimism around biotech pipeline progress and renewable energy expansion.